Hamilton Depression Rating Scale (HAMD-17)

Abstract

The Hamilton Depression Rating Scale (HAMD, HDRS, or Ham-D), originally developed by British psychiatrist Max Hamilton in 1960, represents the historical benchmark and most widely employed clinician-administered assessment instrument for evaluating the severity of depressive symptoms in adults. Although originally designed as a 21-item rating inventory, the 17-item version (HAMD-17) was formally adopted by the National Institute of Mental Health (NIMH) Early Clinical Drug Evaluation Unit (ECDEU) and regulatory bodies worldwide as the standard primary outcome measure in psychopharmacological clinical trials for major depressive disorder (MDD). The instrument evaluates four primary phenomenological domains: affective/mood symptoms (e.g., depressed mood, guilt, suicidal ideation), cognitive symptoms (e.g., hypochondriasis, impaired insight), behavioral manifestations (e.g., psychomotor retardation, agitation, impairment in work and activities), and vegetative/somatic disturbances (e.g., early, middle, and late insomnia, gastrointestinal symptoms, general somatic complaints, genital symptoms, and weight loss). Items are scored on either a 3-point (0 to 2) or 5-point (0 to 4) graded continuum representing escalating severity, frequency, or functional disruption during the preceding week, yielding a cumulative score ranging from 0 to 52 (or up to 54 depending on weighting variants). Psychometrically, the HAMD-17 demonstrates robust inter-rater reliability (intraclass correlation coefficients typically ranging between .80 and .95 when structured interviews are utilized), moderate-to-good internal consistency (Cronbach’s alpha between .70 and .84), and proven sensitivity to pharmacotherapeutic change. However, psychometric critiques, notably those advanced by Bagby and colleagues, highlight multidimensionality, substantial item weighting toward somatic and anxiety symptoms at the expense of atypical neurovegetative features, and poor fit to unidimensional item response theory models. Despite these psychometric caveats, the HAMD-17 remains the global reference standard against which contemporary antidepressants and novel somatic interventions are judged.

Keywords

Hamilton Depression Rating Scale, HAMD-17, HDRS, depression severity, clinician-rated scale, psychometrics, clinical trials, affective disorders, melancholia, psychopharmacology, inter-rater reliability, construct validity, treatment outcome

Authors

The Hamilton Depression Rating Scale was authored by Max Hamilton, M.D., F.R.C.P., F.R.C.Psych. (1912–1988), an eminent German-born British psychiatrist who served as the Nuffield Professor of Psychiatry at the University of Leeds from 1964 to 1977. Hamilton was a foundational pioneer in the burgeoning field of clinical psychometrics and clinical trials methodology during the mid-twentieth century. He served as the President of the British Psychological Society from 1972 to 1973 and played an instrumental role in shaping standardized observational criteria for affective and anxiety disorders, also authoring the companion Hamilton Anxiety Rating Scale (HAM-A) in 1959.

Later standardized administration protocols and structured interview guides were developed by psychometricians and clinical researchers, most notably Janet B. W. Williams, D.S.W., at the New York State Psychiatric Institute and Columbia University College of Physicians and Surgeons, who formalized the Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D) in 1988 to mitigate inter-rater variance and enhance scoring reproducibility across academic medical centers and multicenter clinical trial networks.

Purpose

The principal objective of the Hamilton Depression Rating Scale is to provide a quantitative, clinician-adjudicated index of the severity of illness in individuals already identified as suffering from depressive states. Max Hamilton explicitly stated in his seminal 1960 treatise that the scale was not devised as a diagnostic instrument to detect the presence or absence of a depressive illness or to differentiate between unipolar depression and other psychiatric conditions. Rather, its singular purpose is to quantify symptom intensity, functional impairment, and illness progression in patients diagnosed with depressive illness, particularly of the endogenous or melancholic type, before, during, and after therapeutic intervention.

Clinical Applications

In routine psychiatric and psychological practice, the HAMD-17 serves as an objective monitoring instrument that captures subtle clinical shifts across both subjective and objective behavioral spheres. Because clinical depression inherently impairs patients’ cognitive processing, self-appraisal, and recall capacity, clinician-rated instruments provide an essential counterweight to self-report inventories (such as the Beck Depression Inventory). The clinician synthesizes verbal self-reports, nonverbal observational cues (e.g., psychomotor retardation, facial expression, posture, inflection), and ancillary information obtained from nursing staff, caregivers, or hospital charts to arrive at an ecologically valid severity index. Routine clinical use enables the identification of treatment resistance, partial response, residual vegetative symptoms, and emergent suicidality.

Research Applications and Clinical Trials

For more than six decades, the HAMD-17 has functioned as the primary benchmark outcome metric mandated by global regulatory bodies, including the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for pivotal Phase II and Phase III registration trials of novel antidepressant agents. Standardized trial endpoints are historically anchored to HAMD-17 thresholds:

• Clinical Response: Universally defined as a ≥50% reduction in total HAMD-17 score from baseline assessment.
• Clinical Remission: Defined as achieving an absolute terminal score ≤7 (or in some rigorous trial designs, ≤5), denoting an essentially asymptomatic clinical presentation.
• Trial Eligibility Criteria: Typical antidepressant trials require minimum entry criteria of HAMD-17 ≥ 18 to 22 to confirm moderate-to-severe baseline illness and prevent floor effects.

Theoretical Rationale

The theoretical rationale governing Hamilton’s selection of scale items was heavily rooted in the clinical psychiatry of the 1950s, which conceptualized severe depressive illness as a biological, systemic disease characterized predominantly by neurovegetative and psychomotor disruption. Hamilton argued that psychological self-reports often failed to register the primary biological signs of melancholia, such as diurnal mood variation, early morning awakening, somatic anxiety, autonomic arousal, and motor retardation. By grounding scoring in observable behavioral decrements and objective physiological shifts, the scale aimed to create a reproducible, clinically grounded measurement paradigm capable of detecting the somatic efficacy of newly introduced tricyclic antidepressants and monoamine oxidase inhibitors.

Psychological Construct

The construct assessed by the HAMD-17 is multidimensional depressive symptom severity, encompassing affective, cognitive, motoric, and vegetative manifestations. Rather than reflecting a narrow psychological state of dysphoria, the scale measures the systemic syndrome of depression.

1. Core Depressive / Affective Dimension

This dimension reflects the psychological and phenomenological core of the depressive episode. It is predominantly indexed by Item 1 (Depressed Mood), which evaluates verbal and non-verbal expressions of gloom, sadness, despondency, hopelessness, and helplessness, ranging from transient sadness revealed only upon direct questioning to overwhelming despair dominating all communication. Item 2 (Feelings of Guilt) assesses self-reproach, pathological culpability, ruminative self-blame, and extreme melancholic delusions where the illness is perceived as divine punishment or where auditory hallucinations berate the patient. Item 3 (Suicide) captures the spectrum of suicidal ideation and action, moving hierarchically from the feeling that life is not worth living, through passive death wishes and active suicidal gestures, to overt, lethal suicidal behavior.

2. Sleep Disturbance / Insomnia Dimension

Sleep disruption is decomposed into three distinct chronological segments, providing granular insight into circadian and sleep-architecture abnormalities characteristic of major affective disorders:

• Early Insomnia (Item 4): Sleep-onset latency, evaluating initial difficulty falling asleep (e.g., exceeding 30 minutes).
• Middle Insomnia (Item 5): Sleep fragmentation, restless tossing, and mid-nocturnal awakenings where the patient gets out of bed.
• Late Insomnia (Item 6): Terminal sleep disruption characterized by early morning awakening (e.g., 2 to 3 hours prior to the desired waking time) with complete inability to resume sleep, a hallmark feature of melancholic depression.

3. Behavioral and Work Impairment Dimension

This sub-construct evaluates the impact of depressive energy deficits and anhedonia on functional capacity. Item 7 (Work and Activities) assesses progressive functional erosion, beginning with subjective feelings of fatigue and incapacity, moving into active loss of interest in vocational and recreational activities, marked decreases in real-world productivity, and eventual total cessation of occupational functioning. Item 8 (Psychomotor Retardation) assesses objective central nervous system slowing, observable through slowed speech, prolonged response latency, impoverishment of thought, blank facial expression, and motor stupor. In direct contrast, Item 9 (Agitation) captures motor restlessness, fidgetiness, pacing, wringing of hands, and lip biting, reflecting severe psychic turmoil.

4. Anxiety Dimension (Psychic and Somatic)

Hamilton recognized that anxiety is an intrinsic concomitant of major depressive episodes. Item 10 (Psychological Anxiety) captures subjective apprehension, internal tension, irritability, and catastrophic worrying over trivial events. Item 11 (Somatic Anxiety) quantifies peripheral, autonomic hyperactivity across organ systems, assessing functional gastrointestinal complaints (dry mouth, flatulence, epigastric cramps), cardiovascular distress (palpitations, precordial discomfort), respiratory hyperventilation, tremor, neurovascular flushing, and urinary frequency.

5. Somatic and Vegetative Dimension

This broad physiological cluster captures generalized neurovegetative collapse. Item 12 (Gastrointestinal Somatic Symptoms) indexes profound loss of appetite, food refusal, and digestive sluggishness. Item 13 (General Somatic Symptoms) tracks systemic musculoskeletal aches, heavy sensations in limbs, head, and back, and overwhelming chronic fatigability. Item 14 (Genital Symptoms) assesses loss of sexual desire, erectile or orgasmic dysfunction, and menstrual irregularities. Item 16 (Loss of Weight) quantifies progressive physiological wasting secondary to nutritional failure.

6. Cognitive Distortion and Illness Awareness

Item 15 (Hypochondriasis) assesses distorted somatic preoccupation, extending from excessive bodily self-absorption and repetitive medical consultations to intractable somatic delusions of physical decay or rotting organs. Item 17 (Insight) indexes clinical awareness of one’s psychiatric condition, distinguishing patients who fully recognize their depressive illness from those who rationalize their condition on physical grounds (e.g., climate, viral infection) or completely deny psychiatric disturbance.

Theoretical Framework

The theoretical framework underpinning the Hamilton Depression Rating Scale is historically situated within classical European descriptive psychiatry and the mid-twentieth-century nosological tradition epitomized by Emil Kraepelin, Aubrey Lewis, and Martin Roth. This tradition drew a fundamental distinction between “endogenous” (autonomous, biologically driven melancholia) and “reactive” or neurotic depressive states.

The Melancholic / Endogenous Paradigm

Hamilton designed the scale within the clinical environment of an inpatient psychiatric population at the St. James’s Hospital in Leeds. During this era, hospitalized depressive patients predominantly presented with profound endogenous presentations characterized by vegetative dysregulation, diurnal rhythm disturbances, psychomotor paralysis, and delusion-like guilt. Consequently, the conceptual framework assumes that depressive illness is a biological disturbance that manifests conspicuously in somatic and physiological systems. This explains why approximately half of the items on the HAMD-17 evaluate physical complaints, autonomic reactivity, sleep architecture, and motor changes. Unlike modern psychological frameworks grounded in cognitive theory (such as Aaron T. Beck’s cognitive triad of negative self, world, and future appraisals), Hamilton’s paradigm placed cognitive distortions in a secondary, symptom-level role rather than viewing them as primary causal mechanisms.

Classical Test Theory Assumptions

From a psychometric theoretical perspective, the HAMD-17 operates under the foundational assumptions of Classical Test Theory (CTT). It assumes that an unobserved, latent continuous trait—depressive severity ($ heta$)—manifests additively across an array of clinical symptoms. The observed total score ($X$) is theorized to equal the true severity score ($T$) plus random measurement error ($E$). The simple summation of item scores presumes that each item provides an incremental, linearly additive contribution to the total index of depression severity, with items bearing higher maximum scores (e.g., Depressed Mood, scored 0–4) mathematically weighted more heavily than items scored on 3-point scales (e.g., Insomnia, scored 0–2).

Validity

Extensive psychometric investigations spanning six decades have evaluated the construct, criterion, convergent, discriminant, and predictive validity of the HAMD-17 across diverse inpatient, outpatient, and community populations.

Convergent Validity

The HAMD-17 displays robust convergent validity when compared against alternative clinician-administered and patient-reported depression measures:

• Montgomery-Åsberg Depression Rating Scale (MADRS): Correlations between HAMD-17 and MADRS are consistently high, ranging between $r = .80$ and $r = .94$ across clinical trials, demonstrating that both instruments measure overlapping symptom profiles, although the MADRS places greater weight on psychological and cognitive core symptoms rather than somatic complaints.
• Beck Depression Inventory (BDI): Correlations with self-reported depression on the BDI typically range from $r = .65$ to $r = .82$. The moderate-to-high magnitude indicates shared variance, while discrepancies frequently reflect differences in rater perspective (clinician observation versus patient subjective experience) and the HAMD’s heavy somatic emphasis.
• Quick Inventory of Depressive Symptomatology (QIDS): Strong convergent validity has been documented with both the clinician-rated (QIDS-C; $r = .86$) and self-report (QIDS-SR; $r = .81$) formats in large trials such as the STAR*D study.

Discriminant Validity

Discriminant validity represents one of the most widely debated psychometric facets of the HAMD-17. Because the scale incorporates multiple items explicitly targeting anxiety (Item 10: Psychological Anxiety; Item 11: Somatic Anxiety), hypochondriasis, and somatic complaints, its correlation with standardized anxiety inventories—such as the Hamilton Anxiety Rating Scale (HAM-A)—is often uncomfortably high, ranging between $r = .60$ and $r = .78$. This elevated correlation reflects real-world clinical comorbidity between major depression and generalized anxiety disorder, but it also demonstrates that the HAMD-17 does not cleanly differentiate pure depressive dysphoria from generalized affective distress and autonomic arousal. Nevertheless, the scale successfully discriminates between clinical depressive disorders and non-affective psychiatric conditions, including schizophrenia and organic cognitive disorders.

Predictive and Criterion-Related Validity

The criterion validity of the HAMD-17 is substantiated by its sensitivity to pharmacotherapeutic, psychotherapeutic, and neurostimulation interventions. The scale consistently captures statistical separation between active antidepressants (SSRIs, SNRIs, tricyclics) and placebo within clinical trial designs, showing mean baseline-to-endpoint score reductions that correlate strongly with global clinical improvement indices, such as the Clinical Global Impressions – Improvement (CGI-I) scale ($r = .75$ to $.85$). Furthermore, post-treatment HAMD-17 scores ≤7 reliably predict lower 1-year relapse rates, lower functional disability, and improved long-term psychosocial recovery, establishing meaningful criterion-related predictive validity.

Reliability

The reliability of the HAMD-17 has been evaluated across multiple methodological paradigms, including internal consistency, test-retest stability, and inter-rater agreement.

Internal Consistency

Published estimates of internal consistency for the HAMD-17 vary considerably across populations, generally yielding Cronbach’s alpha ($lpha$) coefficients ranging from $.70$ to $.84$. In a comprehensive psychometric meta-review by Bagby et al. (2004), internal consistency coefficients across 42 published studies had a mean alpha of $.74$. While acceptable for broad group-level clinical trials, this modest level of internal consistency falls short of the ideal benchmark ($lpha ge .90$) for individual diagnostic decision-making, directly reflecting the clinical and statistical multidimensionality of the 17 items.

Inter-Rater Reliability

Because the HAMD is a clinician-rated instrument, inter-rater reliability is paramount. When administered by experienced, calibrated raters using unstructured interviews, inter-rater intraclass correlation coefficients (ICCs) or Pearson correlation coefficients generally range from $.75$ to $.88$. However, when administered using standardized, semi-structured clinical interview protocols—specifically the Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D) developed by Williams (1988)—inter-rater reliability increases significantly, yielding ICCs consistently between $.88$ and $.96$, with individual item weighted kappa ($kappa$) values ranging from $.65$ to $.91$. Standardized video-rater calibration programs, such as those evaluated by Kobak and colleagues (2003) and Müller and Dragicevic (2003), confirm that systematic training ensures uniform scoring across multi-site international clinical investigations.

Test-Retest Reliability

Short-term test-retest reliability over intervals of 24 to 72 hours (in stable, untreated psychiatric cohorts) yields stability coefficients ranging from $r = .81$ to $r = .92$. Over longer intervals (e.g., 2 to 6 weeks), test-retest correlations intentionally decrease, reflecting the scale’s acute sensitivity to clinical change and spontaneous symptom remission.

Factor Analysis

Over sixty years of psychometric exploration, exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) have repeatedly challenged the assumption that the HAMD-17 measures a single, unidimensional depressive construct. Instead, factor solutions consistently reveal a complex, multidimensional latent architecture.

Canonical Factor Structures

The most widely recognized factor structure was documented by Cleary and Guy (1976) within the NIMH Early Clinical Drug Evaluation Unit (ECDEU), which identified six distinct underlying factors:

1. Core Depressive Factor: Comprising Depressed Mood (Item 1), Guilt (Item 2), Suicide (Item 3), and Psychomotor Retardation (Item 8).
2. Sleep Disturbance Factor: Comprising Early Insomnia (Item 4), Middle Insomnia (Item 5), and Late Insomnia (Item 6).
3. Anxiety / Somatization Factor: Comprising Psychological Anxiety (Item 10), Somatic Anxiety (Item 11), Somatic Symptoms Gastrointestinal (Item 12), and Somatic Symptoms General (Item 13).
4. Activity / Impairment Factor: Comprising Work and Activities (Item 7) and Psychomotor Agitation (Item 9).
5. Hypochondriacal / Cognitive Factor: Comprising Hypochondriasis (Item 15) and Insight (Item 17).
6. Genital / Weight Factor: Comprising Genital Symptoms (Item 14) and Weight Loss (Item 16).

Bech’s Melancholia Subscale (HAMD-6)

In response to the multidimensional fragmentation of the full scale, Per Bech and colleagues (1975, 1981) conducted rigorous Rasch item-response analyses and discovered that only six items conform to a strict unidimensional latent continuum of core depressive severity:

• Item 1: Depressed Mood
• Item 2: Feelings of Guilt
• Item 7: Work and Activities
• Item 8: Psychomotor Retardation
• Item 10: Psychological Anxiety
• Item 13: Somatic Symptoms General

This subscale, known as the Bech-6 or HAMD-6, demonstrates pure unidimensionality, monotonicity, higher effect sizes in antidepressant clinical trials, and superior freedom from somatic medication side-effect artifacts compared to the composite HAMD-17.

Modern Confirmatory Factor Analyses and Bifactor Modeling

Modern structural equation modeling and CFA studies examining large clinical trial datasets (e.g., Rush et al., 2003; Bagby et al., 2004) indicate that single-factor models exhibit poor model fit (Comparative Fit Index [CFI] < .85, Root Mean Square Error of Approximation [RMSEA] > .08). In contrast, bifactor models—specifying a general depressive severity factor alongside orthogonal group factors for sleep disturbance, somatic anxiety, and neurovegetative decline—consistently achieve acceptable fit indices (CFI > .94, RMSEA < .05). These structural findings emphasize that the total sum score aggregates diverse physiological and psychological symptom dimensions.

Instrument / Measurement Tool

• Instrument Name: Hamilton Depression Rating Scale (HAMD, HDRS, Ham-D; standard 17-item version: HAMD-17).
• Administration Format: Clinician-administered semi-structured clinical interview, complemented by non-verbal behavioral observation, medical chart documentation, and collateral nursing or family reports.
• Target Population: Adult psychiatric patients (aged 18 and older) clinically diagnosed with a primary depressive disorder.
• Administration Time: Approximately 20 to 30 minutes for a comprehensive diagnostic or monitoring interview (15 to 20 minutes when utilizing standardized structured guides such as the SIGH-D).
• Recall Period: Past 7 days prior to interview (standard clinical trial frame), though some inpatient protocols rate symptoms over the preceding 72 hours.
• Number of Items: 17 items included in standard regulatory scoring (supplementary variants include 21, 24, or 29 items designed to capture atypical depressive features or diurnal shifts).
• Item Response Format: Graded behavioral anchor continuum:
  • Eight items (Items 1, 2, 3, 7, 8, 9, 10, 11) are scored on a 5-point scale: $0 = \text{Absent}$, $1 = \text{Mild / Occasional}$, $2 = \text{Moderate}$, $3 = \text{Severe}$, $4 = \text{Incapacitating / Extreme}$.
  • Nine items (Items 4, 5, 6, 12, 13, 14, 15, 16, 17) are scored on a 3-point scale: $0 = \text{Absent}$, $1 = \text{Mild / Doubtful}$, $2 = \text{Definite / Severe}$ (with specific operational criteria for intermediate or unassessed responses).
• Scoring and Quantification: The total score is computed via simple unweighted summation of Items 1 through 17. The theoretical score range spans from 0 to 52 (or up to 54 in protocols that assign alternative upper limits to Item 16 or Item 15).
• Clinical Severity Cut-Off Score Guidelines:
  • 0 – 7: Normal / Asymptomatic (Remission benchmark)
  • 8 – 16: Mild Depression
  • 17 – 23: Moderate Depression
  • ≥ 24: Severe Depression

Permissions & Fee and Test Year

The Hamilton Depression Rating Scale was first formulated and published by Max Hamilton in 1960 in the Journal of Neurology, Neurosurgery, and Psychiatry, followed by an updated item analysis and modification in 1967. Because the original development of the instrument was sponsored within academic and clinical public health settings and published in scientific literature prior to modern proprietary clinical software regimes, the core HAMD-17 items and their standard anchors reside in the public domain. Researchers and clinicians may utilize, reproduce, and administer the scale without paying royalty fees or licensing charges.

However, specific standardized interview training packages, commercial electronic clinical outcome assessment (eCOA) implementations, and proprietary structured interview guides (such as copyrighted commercial variants of the SIGH-D, computerized adaptive formats, or translations published within proprietary psychometric compendiums) may be subject to institutional copyright, commercial user fees, or formal licensing from publishers and distribution entities.

References

• Bagby, R. M., Ryder, A. G., Schuller, D. R., & Marshall, M. B. (2004). The Hamilton Depression Rating Scale: Has the gold standard become a lead weight? American Journal of Psychiatry, 161(12), 2163–2177. https://doi.org/10.1176/appi.ajp.161.12.2163
• Bech, P., Gram, L. F., Dein, E., Jacobsen, O., Vitger, J., & Bolwig, T. G. (1975). Quantitative rating of depressive states. Acta Psychiatrica Scandinavica, 51(3), 161–170. https://doi.org/10.1111/j.1600-0447.1975.tb00222.x
• Bech, P., Allerup, P., Gram, L. F., Reisby, N., Rosenberg, R., Jacobsen, O., & Nagy, A. (1981). The Hamilton Depression Scale. Evaluation of objectivity using logistic models. Acta Psychiatrica Scandinavica, 63(3), 290–299. https://doi.org/10.1111/j.1600-0447.1981.tb00676.x
• Cleary, P., & Guy, W. (1976). Factor analysis of the Hamilton Depression Scale. In W. Guy (Ed.), ECDEU Assessment Manual for Psychopharmacology (pp. 193–198). National Institute of Mental Health.
• Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry, 23(1), 56–62. https://doi.org/10.1136/jnnp.23.1.56
• Hamilton, M. (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6(4), 278–296. https://doi.org/10.1111/j.2044-8260.1967.tb00530.x
• Kobak, K. A., Lipsitz, J. D., Feiger, A., & Engelhardt, N. (2003). Development of a standardized training program for the Hamilton Depression Scale using internet-based technologies: Results from a pilot study. Journal of Psychiatric Research, 37(6), 509–515. https://doi.org/10.1016/S0022-3956(03)00074-6
• Müller, M. J., & Dragicevic, A. (2003). Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices. Journal of Affective Disorders, 77(1), 65–69. https://doi.org/10.1016/S0165-0327(02)00098-9
• Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., Thase, M. E., Kocsis, J. H., & Keller, M. B. (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 54(5), 573–583. https://doi.org/10.1016/S0006-3223(02)01866-8
• Williams, J. B. (1988). A structured interview guide for the Hamilton Depression Rating Scale. Archives of General Psychiatry, 45(8), 742–747. https://doi.org/10.1001/archpsyc.1988.01800320058007
• Zimmerman, M., & Coryell, W. (1989). Diagnostic efficiency of the Hamilton Depression Rating Scale. Archives of General Psychiatry, 46(8), 796–804. https://doi.org/10.1001/archpsyc.1989.01810090022004

13. Items of the Scale (Questionnaire)